The Use of Tranexamic Acid in Total Ankle Arthroplasty
Category: Ankle Arthritis Introduction/Purpose: The number of total ankle arthroplasties (TAA) is on the rise. Complications associated with TAA include need for blood transfusion, deep vein thrombosis, hematoma, infection, and wound complications. Tranexamic acid (TXA) use in the total knee and tot...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-10-01
|
| Series: | Foot & Ankle Orthopaedics |
| Online Access: | https://doi.org/10.1177/2473011419S00283 |
| _version_ | 1818243665862066176 |
|---|---|
| author | Laura Luick MD Vytas Ringus MD Garrett Steinmetz MD Spencer Falcon MD Shaun Tkach MD Amgad Hallem MD |
| author_facet | Laura Luick MD Vytas Ringus MD Garrett Steinmetz MD Spencer Falcon MD Shaun Tkach MD Amgad Hallem MD |
| author_sort | Laura Luick MD |
| collection | DOAJ |
| description | Category: Ankle Arthritis Introduction/Purpose: The number of total ankle arthroplasties (TAA) is on the rise. Complications associated with TAA include need for blood transfusion, deep vein thrombosis, hematoma, infection, and wound complications. Tranexamic acid (TXA) use in the total knee and total hip population has been found to decrease the rate of blood transfusion. The rate of infections and blood transfusions in TAA was reported to be 3.2% and 1.3%, respectively. In calcaneal fractures TXA was found to decrease wound complications. Our goal was to evaluate the use of TXA in the TAA population to see if its use decreases blood loss or wound complications. Methods: This is a retrospective review of two patient cohorts operated on by a single surgeon from 2010 to 2016. We compared a group of TAA patients that did not receive TXA versus a subsequent group that received TXA. Patients received 1 g IV TXA before tourniquet was inflated and another 1 g following the release of the tourniquet. Pre-operative hemoglobin and hematocrit levels were compared to postoperative levels. Post-operative complications were compared between the two groups. Results: 87 patients were included in the study. 35 patients (40%) received TXA. In patients that received TXA, 18 had postoperative hemoglobin levels available. These patients were compared to a control cohort of 52 patients that did not receive TXA. No significant difference existed between the two groups in gender or age (p=0.9; p=0.7 respectively). Mean estimated blood loss was the same between the two groups. Overall postoperative complications, including wound complications, were higher in the TXA group at 26% vs 12% but this was not statistically significant (p-value = 0.086). The preoperative to postoperative change in hemoglobin/hematocrit levels was not statistically significant between groups (p-value = 0.78). There was one transfusion required in the non-TXA group and no transfusions required in the TXA group (p=0.9). Conclusion: The use of TXA was not found to provide a beneficial effect in total ankle arthroplasty in either decreasing wound complications or blood loss. Given these results, TXA use might not be cost effective in total ankle arthroplasty as opposed to other total joint arthroplasties. Further higher levels studies with increased number of patients are required to further evaluate TXA effectiveness in TAA. |
| first_indexed | 2024-12-12T14:04:45Z |
| format | Article |
| id | doaj.art-f071d96a274c46c7b904216c29b87b6a |
| institution | Directory Open Access Journal |
| issn | 2473-0114 |
| language | English |
| last_indexed | 2024-12-12T14:04:45Z |
| publishDate | 2019-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Foot & Ankle Orthopaedics |
| spelling | doaj.art-f071d96a274c46c7b904216c29b87b6a2022-12-22T00:22:16ZengSAGE PublishingFoot & Ankle Orthopaedics2473-01142019-10-01410.1177/2473011419S00283The Use of Tranexamic Acid in Total Ankle ArthroplastyLaura Luick MDVytas Ringus MDGarrett Steinmetz MDSpencer Falcon MDShaun Tkach MDAmgad Hallem MDCategory: Ankle Arthritis Introduction/Purpose: The number of total ankle arthroplasties (TAA) is on the rise. Complications associated with TAA include need for blood transfusion, deep vein thrombosis, hematoma, infection, and wound complications. Tranexamic acid (TXA) use in the total knee and total hip population has been found to decrease the rate of blood transfusion. The rate of infections and blood transfusions in TAA was reported to be 3.2% and 1.3%, respectively. In calcaneal fractures TXA was found to decrease wound complications. Our goal was to evaluate the use of TXA in the TAA population to see if its use decreases blood loss or wound complications. Methods: This is a retrospective review of two patient cohorts operated on by a single surgeon from 2010 to 2016. We compared a group of TAA patients that did not receive TXA versus a subsequent group that received TXA. Patients received 1 g IV TXA before tourniquet was inflated and another 1 g following the release of the tourniquet. Pre-operative hemoglobin and hematocrit levels were compared to postoperative levels. Post-operative complications were compared between the two groups. Results: 87 patients were included in the study. 35 patients (40%) received TXA. In patients that received TXA, 18 had postoperative hemoglobin levels available. These patients were compared to a control cohort of 52 patients that did not receive TXA. No significant difference existed between the two groups in gender or age (p=0.9; p=0.7 respectively). Mean estimated blood loss was the same between the two groups. Overall postoperative complications, including wound complications, were higher in the TXA group at 26% vs 12% but this was not statistically significant (p-value = 0.086). The preoperative to postoperative change in hemoglobin/hematocrit levels was not statistically significant between groups (p-value = 0.78). There was one transfusion required in the non-TXA group and no transfusions required in the TXA group (p=0.9). Conclusion: The use of TXA was not found to provide a beneficial effect in total ankle arthroplasty in either decreasing wound complications or blood loss. Given these results, TXA use might not be cost effective in total ankle arthroplasty as opposed to other total joint arthroplasties. Further higher levels studies with increased number of patients are required to further evaluate TXA effectiveness in TAA.https://doi.org/10.1177/2473011419S00283 |
| spellingShingle | Laura Luick MD Vytas Ringus MD Garrett Steinmetz MD Spencer Falcon MD Shaun Tkach MD Amgad Hallem MD The Use of Tranexamic Acid in Total Ankle Arthroplasty Foot & Ankle Orthopaedics |
| title | The Use of Tranexamic Acid in Total Ankle Arthroplasty |
| title_full | The Use of Tranexamic Acid in Total Ankle Arthroplasty |
| title_fullStr | The Use of Tranexamic Acid in Total Ankle Arthroplasty |
| title_full_unstemmed | The Use of Tranexamic Acid in Total Ankle Arthroplasty |
| title_short | The Use of Tranexamic Acid in Total Ankle Arthroplasty |
| title_sort | use of tranexamic acid in total ankle arthroplasty |
| url | https://doi.org/10.1177/2473011419S00283 |
| work_keys_str_mv | AT lauraluickmd theuseoftranexamicacidintotalanklearthroplasty AT vytasringusmd theuseoftranexamicacidintotalanklearthroplasty AT garrettsteinmetzmd theuseoftranexamicacidintotalanklearthroplasty AT spencerfalconmd theuseoftranexamicacidintotalanklearthroplasty AT shauntkachmd theuseoftranexamicacidintotalanklearthroplasty AT amgadhallemmd theuseoftranexamicacidintotalanklearthroplasty AT lauraluickmd useoftranexamicacidintotalanklearthroplasty AT vytasringusmd useoftranexamicacidintotalanklearthroplasty AT garrettsteinmetzmd useoftranexamicacidintotalanklearthroplasty AT spencerfalconmd useoftranexamicacidintotalanklearthroplasty AT shauntkachmd useoftranexamicacidintotalanklearthroplasty AT amgadhallemmd useoftranexamicacidintotalanklearthroplasty |